Inhibitory Effects of Deoxypodophyllotoxin from Anthriscus sylvestris on Human CYP2C9 and CYP3A4

Abstract

Deoxypodophyllotoxin (DPT) is a bioactive compound of Anthriscus sylvestris (Apiaceae). In the present study, the inhibition of cytochrome P450 (CYP) by DPT was evaluated in human liver microsomes (HLM) and the baculovirus-insect cell-expressed human CYPs using a cocktail probe assay. When a mixture of specific CYP substrates was incubated with DPT in HLM, CYP2C9-catalyzed diclofenac 4-hydroxylation and CYP3A4-catalyzed midazolam 1-hydroxylation were strongly inhibited by DPT, with IC₅₀ values of 6.3 and 9.2 µM, respectively. The Lineweaver-Burke plots for the inhibition of CYP2C9 and CYP3A4 in HLM and baculovirus-insect cell-expressed human CYPs were consistent with a competitive type of inhibition. From these results, DPT was characterized to be a competitive inhibitor of CYP2C9 and CYP3A4, with K _i values of 3.5 and 10.8 µM in HLM and 24.9 and 3.5 µM in baculovirus-insect cell-expressed human CYPs, respectively.

Key words

deoxypodophyllotoxin - cytochrome P450 - competitive inhibition - cocktail probe assay - Anthriscus sylvestris - Apiaceae

References

• 1 Wong S K, Tsui S K, Kwan S Y, Su X L, Lin R C. Identification and characterization of Podophyllum emodi by API-LC/MS/MS.  J Mass Spectrom. 2000;  35 1246-1251
• 2 Koulman A, Beekman A C, Pras N, Quax W J. The bioconversion process of deoxypodophyllotoxin with Linum flavum cell cultures.  Planta Med. 2003;  69 739-744
• 3 Ikeda R, Nagao T, Okabe H, Nakano Y, Matsunaga H, Katano M, Mori M. Antiproliferative constituents in Umbelliferae plants. IV. Constituents in the fruits of Anthriscus sylvestris Hoffm.  Chem Pharm Bull. 1998;  46 875-878
• 4 Chen J J, Chang Y L, Teng C M, Chen I S. Anti-platelet aggregation alkaloids and lignans from Hernandia nymphaeifolia.  Planta Med. 2000;  66 251-256
• 5 Gordaliza M, Castro M A, Garcia-Gravalos M D, Ruiz P, Miguel del Corral J M, San Feliciano A. Antineoplastic and antiviral activities of podophyllotoxin related lignans.  Arch Pharm. 1994;  327 175-179
• 6 Sudo K, Konno K, Shigeta S, Yokota T. Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication.  Antivir Chem Chemother. 1998;  9 263-267
• 7 Lee S H, Son M J, Ju H K, Lin C X, Moon T C, Choi H, Son J K, Chang H W. Dual inhibition of cyclooxygenases-2 and 5-lipoxygenase by deoxypodophyllotoxin in mouse bone marrow-derived mast cells.  Biol Pharm Bull. 2004;  27 786-788
• 8 Jin M, Moo T C, Quan Z Q, Lee E, Kim Y K, Yang J H, Suh S, Jeong T C, Lee S H, Kim C, Chang H W. The naturally occurring flavolignan, deoxypodophyllotoxin, inhibits lipopolysaccharide-induced iNOS expression through the NF-kappaΒ activation in RAW264.7 macrophage cells.  Biol Pharm Bull. 2008;  31 1312-1315
• 9 Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract.  Drug Metab Pharmacokinet. 2005;  20 34-45
• 10 Chiba M, Nishime J A, Chen I, Vastag K J, Sahly Y S, Kim B M, Dorsey B D, Vacca J P, Lin J H. Metabolite-P450 complex formation by methylenedioxyphenyl HIV protease inhibitors in rat and human liver microsomes.  Biochem Pharmacol. 1998;  56 223-230
• 11 Julsing M K, Vasilev N P, Schneidman-Duhovny D, Muntendam R, Woerdenbag H J, Quax W J, Wolfson H J, Ionkova I, Kayser O. Metabolic stereoselectivity of cytochrome P450 3A4 towards deoxypodophyllotoxin: in silico predictions and experimental validation.  Eur J Med Chem. 2008;  43 1171-1179
• 12 Yoo H H, Lee S H, Jin C B, Kim D H. Mechanism-based inactivation of cytochrome P450 3A4 by methylenedioxyphenyl lignans from Acanthopanax chiisanensis.  Planta Med. 2008;  74 822-827
• 13 Philpot R M, Hodgson E A. A cytochrome P-450-piperonyl butoxide spectrum similar to that produced by ethyl isocyanide.  Life Sci. 1971;  10 503-512
• 14 Mathews J M, Etheridge A S, Black S R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones.  Drug Metab Dispos. 2002;  30 1153-1157
• 15 Usia T, Watabe T, Kadota S, Tezuka Y. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition.  Life Sci. 2005;  76 2381-2391
• 16 Lee S K, Jun I H, Yoo H H, Kim J H, Seo Y M, Kang M J, Lee S H, Jeong T C, Kim D H. Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry.  Rapid Commun Mass Spectrom. 2008;  22 52-58
• 17 Palmer T. Understanding enzymes, 4th edition. Hertfordshire; Prentice Hall/Ellis Horwood 1995: 128-154
• 18 Vasilev N P, Julsing M K, Koulman A, Clarkson C, Woerdenbag H J, Ionkova I, Bos R, Jaroszewski J W, Kayser O, Quax W J. Bioconversion of deoxypodophyllotoxin into epipodophyllotoxin in E. coli using human cytochrome P450 3A4.  J Biotechnol. 2006;  126 383-393
• 19 Kumar V, Wahlstrom J L, Rock D A, Warren C J, Gorman L A, Tracy T S. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.  Drug Metab Dispos. 2006;  34 1966-1975
• 20 Tang W, Stearns R A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions.  Curr Drug Metab. 2001;  2 185-198
• 21 He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes.  Am J Ther. 2004;  11 206-212
• 22 Yun C H, Shimada T, Guengerich F P. Purification and characterization of human liver microsomal cytochrome P-450 2A6.  Mol Pharmacol. 1991;  40 679-685
• 23 Tassaneeyakul W, Birkett D J, Veronese M E, McManus M E, Tukey R H, Quattrochi L C, Gelboin H V, Miners J O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.  J Pharmacol Exp Ther. 1993;  265 401-407
• 24 Wrighton S A, Stevens J C, Becker G W, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation.  Arch Biochem Biophys. 1993;  306 240-245
• 25 Thummel K E, Shen D D, Podoll T D, Kunze K L, Trager W F, Bacchi C E, Marsh C L, McVicar J P, Barr D M, Perkins J D. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.  J Pharmacol Exp Ther. 1994;  271 549-556
• 26 Dierks E A, Stams K R, Lim H K, Cornelius G, Zhang H, Ball S E. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450 s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry.  Drug Metab Dispos. 2001;  29 23-29